Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3; which leads to an hyper-methylated region in the gene promoter therefore silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.
Epidemiology Insights
Market Insight
Fragile X Syndrome market size in 7MM in 2017 was USD 33.8 Million
Fragile X Syndrome Market Drivers
Fragile X Syndrome Market Barriers
Key benefits of the report
1. Fragile X Syndrome market report covers a descriptive overview and comprehensive insight of the Fragile X Syndrome epidemiology and Fragile X Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Fragile X Syndrome market report provides insights into the current and emerging therapies.3. Fragile X Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Fragile X Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fragile X Syndrome market.
Table of contents
1. Key Insights2. Executive summary3. Organisations4. Fragile X Syndrome Epidemiology and Market Methodology5. Fragile X Syndrome Market Overview at a Glance6. Fragile X Syndrome Disease Background and Overview7. Fragile X Syndrome Epidemiology and Patient Population7.1. Key Findings7.2. Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM7.3. United States7.4. EU57.5. Assumptions and Rationale7.6. Germany7.7. France7.8. Italy7.9. Spain7.10. United Kingdom (UK)7.11. Japan8. Fragile X Syndrome Current Treatment9. Unmet Need10. Fragile X Syndrome Emerging Drugs10.1. Key Cross Competition10.2. Cannabidiol: Zynerba Pharmaceuticals10.3. Acamprosate: Confluence Pharmaceuticals10.4. BPN14770: Tetra Therapeutics10.5. OV101: Ovid Therapeutics10.6. Trofinetide: Neuren Pharmaceuticals11. Fragile X Syndrome Market Size12. Fragile X Syndrome Market Outlook: 7 MM12.1. United States12.2. EU512.3. Germany12.4. France12.4.3. Italy12.5. Spain12.6. United Kingdom12.7. Japan13. Market Drivers14. Market Barriers15. SWOT analysis16. Cases studies17. KOL Views18. Appendix19. DelveInsight Capabilities20. Disclaimer21. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/